All In Biotech

Drug Trial Radar · NCT06837155

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Mar 3, 2025

Primary completion

May 20, 2025

Study completion May 26, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 39 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

Conditions

  • Healthy Volunteers

Interventions

  • TS-172 20 mgDrug

    oral administration of TS-172 20 mg

  • TS-172 90 mgDrug

    oral administration of TS-172 90 mg

  • MoxifloxacinDrug

    oral administration of moxifloxacin 400 mg

  • PlaceboDrug

    oral administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QTcF:QT-interval corrected by Fridericia corrections in Holter ECGsTime frame: Up to 24 hours postdose during each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.